drugset
drugset / Trial / NCT04801693

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food

NCT04801693 ↗

Phase 1 Completed 66 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of the single rising doses (SRD) trial part are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy male subjects following administration of single rising doses. The main objective of the food effect part is to investigate the influence of food on the relative bioavailability of BI 1819479.

Timeline

Start
2021-05-26
Primary completion
2022-04-25
Completion
2022-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1819479 Unknown — —

Indications

No indication recorded.